After the US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee largely voted against Biogen, Inc.’s Alzheimer’s disease treatment Aduhelm (aducanumab) in November 2020, the Alzheimer’s Association took action, apparently to combat the negative sentiment.
Patient Support May Have Helped Push Aduhelm Toward Approval
After largely negative advisory committee meeting, a patient group held a listening session with the FDA to be sure their voices were heard during the review of Biogen's aducanumab.
